{"filing":{"accession_number":"0001654954-26-006601","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-07-10","report_date":null,"primary_document":"a9298l.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426006601/a9298l.htm"},"events":[{"id":16975,"run_id":15199,"accession_number":"0001654954-26-006601","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This disclosure announces positive Phase III clinical trial results (ARTEMIS-008) for risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate, demonstrating statistically significant overall survival improvements in advanced/relapsed small-cell lung cancer. While the announcement concerns a clinical development milestone rather than a discrete corporate event (M\u0026A, executive change, financial obligation, or accounting matter), it represents a material operational/strategic development affecting GSK's oncology pipeline and regulatory prospects. The positive Phase III data, regulatory designations (Breakthrough Therapy, Orphan Drug, PRIME), and advancement of the global development program constitute material information affecting investor assessment of GSK's product portfolio and future commercial potential.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-10","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":15244,"accession_number":"0001654954-26-006601","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces positive Phase III clinical trial results (ARTEMIS-008) for risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate, demonstrating statistically significant overall survival improvements in advanced/relapsed small-cell lung cancer. While the announcement concerns a clinical development milestone rather than a discrete corporate event (M\u0026A, executive change, financial obligation, or accounting matter), it represents a material operational/strategic development affecting GSK's oncology pipeline and regulatory prospects. The positive Phase III data, regulatory designations (Breakthrough Therapy, Orphan Drug, PRIME), and advancement of the global development program constitute material information affecting investor assessment of GSK's product portfolio and future commercial potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:14:37.506153+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-10"}]}